Pretax income is the income that a company earns before paying income taxes. Plus Therapeutics's pretax income for the
three
months ended in Dec. 2023 was $-3.81 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-13.32 Mil.
Plus Therapeutics's pretax margin was %.
During the past 13 years, Plus Therapeutics's highest Pretax Margin was -46.91%. The lowest was -2719.80%. And the median was -297.62%.
Plus Therapeutics Pre-Tax Income Historical Data
The historical data trend for Plus Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Plus Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, Plus Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Plus Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Plus Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Plus Therapeutics's Pre-Tax Income falls into.
Plus Therapeutics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Plus Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Plus Therapeutics (NAS:PSTV) Pre-Tax Income Explanation
Plus Therapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 13 years, Plus Therapeutics's highest Pretax Margin was -46.91%. The lowest was -2719.80%. And the median was -297.62%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Plus Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Plus Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Plus Therapeutics (Plus Therapeutics) Business Description
Plus Therapeutics Inc is a clinical-stage pharmaceutical company. The company focused on the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Its product pipeline includes Patented RNL and Patented DocePLUS.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PSTV has been successfully added to your 